



This patient group direction (PGD) must only be used by registered health professionals who have been named and authorised by their organisation to practice under it. The most recent and in date final signed version of the PGD should be used.

Patient Group Direction (PGD)

For the administration of

Hyoscine Hydrobromide 400 micrograms/ml solution for injection

By registered health care professionals for

excessive respiratory secretions in palliative care

Throughout the Manx Care and those contracted by the Manx Care where appropriate within practice

PGD NUMBER 30

1. Change history

| Version number | Change details | Date |
|----------------|---|-------------------------|
| 1 | Original PGD ratified | June 2021 |
| 2 | Minor word changes to ensure clarify of PGD and links added to Cautions and Adverse Effects, and reference to Manx Care Policy for Capacity added. Plus: <ul style="list-style-type: none">including removing supply (administration only)adding form and strength to title page | March 2023 and May 2024 |

2.

Reference number: 30

Valid from: 03/2023. Review date: 03/2025. Expiry date: 03/2026

Version: 2

3. Medicines practice guideline 2: *Patient group directions*

Refer to the relevant sections of NICE medicines practice guideline 2: *Patient group directions* as stated in the blank template notes. For further information about PGD signatories, see the NHS and Manx Care [PGD website FAQs](#)

4. PGD development

Refer to [the NICE PGD competency framework for people developing PGDs](#)

| Job Title & organisation | Name | Signature | Date |
|---------------------------------|------|-----------|------|
| Author of the PGD | | | |
| Member of the PGD working group | | | |

5. PGD authorisation

Refer to the [NICE PGD competency framework for people authorising PGDs](#)

| Pre Signatures | | | |
|--|------|-----------|------|
| Job Title | Name | Signature | Date |
| Chief Pharmacist | | | |
| Head of Ambulance Services | | | |
| GP Adviser | | | |
| Senior Microbiologist (if PGD contains antimicrobials) | N/A | N/A | N/A |
| Final signatures | | | |
| Medical Director | | | |
| Director of Nursing | | | |

6. Training and competency of registered healthcare professionals, employed or contracted by the Manx Care, GP practice or Hospice

Refer to the [NICE PGD competency framework for health professionals using PGDs](#)

| | Requirements of registered Healthcare professionals working under the PGD |
|---|---|
| Qualifications and professional registration | <ul style="list-style-type: none"> Registered healthcare professionals, working within or contracted by the Manx Care, GP practice or Hospice who are permitted staff groups outlined within the current PGD policy |
| Initial training | <ul style="list-style-type: none"> Knowledge of current guidelines and the administration of the drug specified in this PGD/BNF and of the inclusion and exclusion criteria Training which enables the practitioner to make a clinical assessment to establish the need for the medication covered by this PGD Local training in the use of PGDs |
| Competency assessment | Staff will be assessed on their knowledge of drugs and clinical assessment as part the competency framework for registered health professionals using PGDs |
| Ongoing training and competency | The registered health care professionals should make sure they are aware of any changes to the recommendations for this medication; it is the responsibility of the registered health care professionals to keep up to date with continuing professional development. PGD updates will be held every two years |

7. Clinical Conditions

| | |
|--|--|
| Clinical condition or situation to which this PGD applies | Excessive respiratory secretions in palliative care |
| Inclusion criteria | Adults 16 years of age and over |
| Exclusion criteria | Individuals under the age of 16 years |
| Cautions (including any relevant action to be taken) (continued ...) | <ul style="list-style-type: none"> Hypersensitivity to any ingredients Epilepsy Acute myocardial infarction Arrhythmias Autonomic neuropathy Cardiac insufficiency (due to association with tachycardia) Cardiac surgery (due to association with tachycardia) Conditions characterised by tachycardia Congestive heart failure (may be worsened) Coronary artery disease (may be worsened) Diarrhoea Elderly (especially if frail) Gastro-oesophageal reflux disease Hiatus hernia with reflux oesophagitis Hypertension |

| | |
|---|---|
| Cautions (including any relevant action to be taken) <i>(... continued)</i> | <ul style="list-style-type: none"> • Hyperthyroidism (due to association with tachycardia) • Individuals susceptible to angle-closure glaucoma • Prostatic hyperplasia (in adults) • Pyrexia • Ulcerative colitis <p>A detailed list of cautions is available in the SPC, which is available from the electronic Medicines Compendium website: www.medicines.org.uk and BNF https://bnf.nice.org.uk</p> |
| Arrangements for referral for medical advice | Patient should be referred to a more experienced clinical practitioner for further assessment |
| Action to be taken if patient excluded | Patient should be referred to a more experienced clinical practitioner for further assessment |
| Action to be taken if patient declines treatment | <ul style="list-style-type: none"> • A verbal explanation should be given to the patient on: the need for the medication and any possible effects or potential risks which may occur as a result of refusing treatment • This information must be documented in the patients' health records • Any patient who declines care must have demonstrated capacity to do so (see the Manx Care Policy for Capacity, Best Interests Decisions and Deprivation of Liberty) • Where appropriate care should be escalated |

8. Details of the medicine

| | |
|--|--|
| Name, form and strength of medicine | Hyoscine Hydrobromide 400 micrograms/ml solution for injection |
| Legal category | Prescription only medicine (POM) |
| Indicate any <u>off-label use</u> (if relevant) | None |
| Route/method of administration | Subcutaneous |
| Dose and frequency | By subcutaneous injection 400 micrograms every 4 hours as required, hourly use is occasionally necessary, particularly in excessive respiratory secretions |
| Quantity to be administered | As per dose – Instruction above |
| Maximum or minimum treatment period | 2mg within 24 hours |
| Storage | Room temperature |

| | |
|---------------------------|--|
| Adverse effects | <ul style="list-style-type: none"> • Constipation • Dizziness • Drowsiness • Dry mouth • Dyspepsia • Flushing • Headache • Nausea • Palpitations • Skin reactions • Tachycardia • Urinary disorders • Vision disorders • Vomiting • Eye disorders • Eyelid irritation <p>A detailed list of adverse reactions is available in the SPC, which is available from the electronic Medicines Compendium website: www.medicines.org.uk and BNF https://bnf.nice.org.uk</p> |
| Records to be kept | The administration of any medication given under a PGD must be recorded within the patient's medical records |

9. Patient information

| | |
|---|--|
| Verbal/Written information to be given to patient or carer | <ul style="list-style-type: none"> • Verbal information must be given to patients and or carers for all medication being administered under a PGD • Where medication is being supplied under a PGD, written patient information leaflet must also be supplied • A patient information leaflet is available on request |
| Follow-up advice to be given to patient or carer | If symptoms do not improve or worsen or you become unwell, seek medical advice immediately |

10. Appendix A

| | |
|--|--|
| References | |
| <ol style="list-style-type: none"> 1. British National Formulary (BNF) available online: https://bnf.nice.org.uk 2. Nursing and Midwifery "The code" available online: https://www.nmc.org.uk 3. Current Health Care Professions Council standards of practice 4. General Pharmaceutical Council standards 5. Electronic medicines compendium available online: https://www.medicines.org.uk 6. Manx Care Policy for Capacity, Best Interests Decisions and Deprivation of Liberty http://edrmgi/sites/hospital/Clinical%20Policies%20and%20Procedures/Policy%20for%20Capacity,%20Best%20Interests%20Decisions%20and%20Deprivation%20of%20Liberty.pdf#search=deprivation | |

11. Appendix B

| | |
|--|--|
| Health professionals agreed to practice | |
| <ul style="list-style-type: none"> • Each registered healthcare professional will hold their own Competency framework which will be signed and agreed by their mentor • A mentor is defined within the Manx Care policy as any ward/area managers, sisters, senior nurses, GPs, pharmacists or senior paramedics who has completed the PGD training themselves | |